Combined therapy may improve clinical responses for endometrial, colorectal and gastric tumours

Google+ Pinterest LinkedIn Tumblr +

A study at The University of Texas MD Anderson Cancer Center, USA, discovered a novel therapeutic vulnerability for patients who have tumours caused by a genetic misfire in the DNA mismatch repair (MMR) pathway, a system for repairing genetic aberrations.

Study findings were published in the journal Cancer Cell.

When tumours lose MMR function, they acquire numerous mutations throughout their DNA which can promote cancer formation.

This deficiency is often found in certain cancers, such as endometrial, colorectal and gastric cancer.

It can be diagnosed through the presence of genetic irregularities known as microsatellite instability (MSI).

“MMR deficient and MSI cancers display resistance to chemotherapy and only a subset responds to immunotherapy, leaving a large number of patients with few treatment options,” said Shiaw-Yih Lin, Ph.D., professor of Systems Biology.

“Our study identified proteome instability as a novel therapeutic vulnerability in MSI tumours.”

Using cell lines, patient samples, mouse models and computational techniques, Lin’s team showed that the abundant mutant proteins in MSI cancers become misshapen and structurally unstable.

As tumour cells shift resources to help correctly shape the mutated proteins, they begin to fail to correctly shape normal proteins, ultimately resulting in all of the proteins within the tumour becoming more unstable.

The abundance of misshapen proteins requires tumour cells to use a protein degradation pathway not typically used by normal cells.

This pathway can be blocked by MLN4924, resulting in toxicity specifically in MSI cancer cells.

In addition to killing the cells, the authors found that treatment with MLN4924 induced an immunogenic form of cell death.

“As the tumour cells were dying following MLN4924 treatment, we observed them secreting molecules to recruit immune cells and expressing a protein instructing immune cells to kill other cells that look like them,” said Daniel McGrail, Ph.D., postdoctoral fellow and the study’s first author.

“By further activating immune cells through dual treatment with anti-PD1, a treatment modality already approved in MSI tumours, we were able to induce durable, curative responses.”

The team saw no toxicities from this therapeutic approach, and are hopeful about the translational prospects as both treatment agents are already in the clinic.


Source: University of Texas M.D. Anderson Cancer Center

Share.

About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.